scholarly journals A case study wistar rats by implementing Metformin on Clozapine

2018 ◽  
Vol 8 (1) ◽  
pp. 5-9
Author(s):  
Vinaya B ◽  
Akila CR ◽  
Dinesh Babu J ◽  
Sravan Kumar P
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Type Ii Diabetes ◽  
Wistar Rats ◽  
Fasting Blood Glucose ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Metabolic Derangement ◽  
Group 2 ◽  
The Impact

The medical studies in beyond decade has reported that maximum 2nd-era antipsychotics (SGAs) can reason severe metabolic derangement, which significantly upsurges the danger for type II diabetes mellitus. Numerous retrospective studies have proven multiplied in serum triglyceride in sufferers handled with Clozapine. SGAs triggered metabolic syndrome is characterized via hypertension, weight gain, hyperglycaemia, hyperlipidaemia, glucose intolerance and insulin resistance. Metformin is presently used to extravagance metabolic syndrome and type II diabetes mellitus. It is consequently essential to decide whether Metformin is effective in discussing Clozapine-brought on metabolic derangement like dyslipidaemia. To appraise the impact of Metformin in minimizing Clozapine caused metabolic irrationality like dyslipidaemia. Methodology: Wistar rats weighing a hundred and eighty-240g both intercourse had been divided into three corporations of 6 rats every. Group 1 attended as manipulate, Group 2 Preserved with Clozapine 25mg/kg frame weight and Group 3 Treated with Clozapine 25mg + Metformin 100mg/kg body weight for 30 days P.O. Group 2 and group three were preserved for 30 days. Lipid profile of institution 2 rats handled with Clozapine showed dyslipidaemia (TG 103.3±1.7mg/dl, Tc 113.7±1.6mg/dl). Whereas organization 3 rats treated with Clozapine 25mg + Metformin confirmed ordinary lipid levels (TG ninety four.7±1.7mg/dl, TC 102.Eight±0.Eight mg/dl) similar to institution 1(TG ninety three.0±2.6mg/dl, TC 103.7±1.5mg/dl). This study focuses a non-substantial increase in fasting blood glucose in SD rodents managed with clozapine that was in part checked by utilizing simultaneous organization of metformin. Rodents controlled clozapine affirmed the anticipated abatement in the statement of GLUT2, anyway simultaneous administration of metformin and clozapine for 30 days didn't show the anticipated standardization of the articulation degrees of GLUT2. This look at investigating the use of Metformin to forestall metabolic unsettling like dyslipidaemias in patients of schizophrenia managed with Clozapine.

scholarly journals ROLE OF METFORMIN ON CLOZAPINE INDUCED DYSLIPIDAEMIA IN WISTAR RATS

2018 ◽  
pp. 1-5
Author(s):  
Syed Shoib Md Hussaini ◽  
Akram A Naikwadi ◽  
Narsapur VU
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Type Ii Diabetes ◽  
Wistar Rats ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Metabolic Derangement ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Background: The clinical research in past decade has reported that most second-generation antipsychotics (SGAs) can cause serious metabolic derangement, which substantially increases the risk for type II diabetes mellitus. Several retrospective studies have shown increased in serum triglyceride in patients treated with Clozapine. SGAs induced metabolic syndrome is characterized by weight gain, hyperglycaemia, hypertension, hyperlipidaemia, glucose intolerance and insulin resistance. Metformin is currently used to treat metabolic syndrome and type II diabetes mellitus. It is therefore important to determine whether Metformin is efficacious in treating Clozapine-induced metabolic derangement like dyslipidaemia. Objectives: To evaluate the effect of Metformin in minimizing Clozapine induced metabolic derangement like dyslipidaemia. Methodology: Wistar rats weighing 180-240g either sex were divided into 3 groups of 6 rats each. Group 1 served as control, Group 2 Treated with Clozapine 25mg/kg body weight and Group 3 Treated with Clozapine 25mg + Metformin 100mg/kg body weight for 28 days P.O. Group 2 and group 3 were treated for 28 days. Biochemical investigations: Retro-orbital blood was collected for Lipid profile. Result: Lipid profile of group 2 rats treated with Clozapine showed dyslipidaemia (TG 103.3 ±1.7mg/dl, Tc 113.7 ±1.6mg/dl). Whereas group 3 rats treated with Clozapine 25mg + Metformin showed normal lipid levels (TG 94.7±1.7mg/dl, TC 102.8 ±0.8 mg/dl) comparable to group 1(TG 93.0 ±2.6mg/dl, TC 103.7 ±1.5mg/dl). Conclusion: This study exploring the use of Metformin to prevent metabolic derangement like dyslipidaemias in patients of schizophrenia treated with Clozapine. KEYWORDS: Clozapine; Metformin; Dyslipidaemia.

scholarly journals Antidiabetic and Antilipidemic Activity of Root Extracts of Salacia oblonga against Streptozotocin-Induced Diabetes in Wistar Rats

Processes ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 301 ◽  
Author(s):  
Kakara Gift Kumar Deepak ◽  
Surekha Challa ◽  
Ganta Suhasin ◽  
Neelapu Nagesewara Rao Reddy ◽  
Hosam O. Elansary ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Wistar Rats ◽  
Type Ii Diabetes Mellitus ◽  
Antidiabetic Activity ◽  
Root Extract ◽  
Dependent Manner ◽  
Type Ii ◽  
Root Extracts ◽  
Salacia Oblonga

Salacia oblonga is used to treat diabetes, hypocholesteremia, gonorrhea, rheumatism, asthma, inflammation, oxidative stress, etc. In the present study, the antidiabetic activity of S. oblonga methanolic root extracts collected from three geographical locations, viz., Eleshwaram (Andhra Pradesh), Thoothukudi (Tamil Nadu), and Karwar (Karnataka), was studied in vitro. Among the three extracts, S. oblonga root extracts from Eleshwaram showed maximum α-glucosidase and α-amylase inhibitory activities, indicating better antidiabetic activity. Acute toxicity studies of S. oblonga carried out in Albino Wistar rats showed no toxicity. Further, in vivo studies showed antidiabetic and antilipidemic activities in Albino Wistar rats with induced type II diabetes mellitus. Type II diabetes mellitus was induced in the experimental rats by intraperitoneal injection of nicotinamide and streptozotocin. The rats were orally fed different doses (ranging from 0 to 400 mg/kg body weight) of S. oblonga root extracts from Eleshwaram for 14 days. Blood glucose, lipid, bilirubin, and creatinine levels were analyzed on day 0, 7, and 14. The S. oblonga root extract from Eleshwaram decreased the glucose levels in a dose-dependent manner as well as the lipid, creatinine, and bilirubin levels in diabetic rats. Thus, the present study demonstrates antidiabetic and antilipidemic properties of S. oblonga root extracts.

Study of Prevalence of Hypomagnesemia in Patients with Type II Diabetes Mellitus

2017 ◽  
Vol 3 (2) ◽  
pp. 55-58 ◽  
Author(s):  
NH Rekha ◽  
MS Bharath ◽  
SP Channakeshava
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Negative Impact ◽  
Serum Magnesium ◽  
Fasting Blood Glucose ◽  
Type Ii Diabetes Mellitus ◽  
Diabetic Patients ◽  
Type Ii ◽  
Major Health ◽  
Medical College

ABSTRACT Introduction Diabetes mellitus is a common metabolic disorder. Prevalence of diabetes is increasing globally and it is one of the major health problems of the 21st century. The disturbance in serum magnesium (SMg) has been reported among patients with type II diabetes mellitus. Hypomagnesemia has negative impact on glucose homeostasis and insulin sensitivity in patients with type II diabetes mellitus. Aim This study was undertaken to know the prevalence of hypomagnesemia in patients with type II diabetes mellitus and its relation with glycated hemoglobin (HbA1c). The study was conducted on 200 patients with type II diabetes and 100 healthy controls at RajaRajeswari Medical College & Hospital, Bengaluru. Results Out of 200 diabetic patients, 115 (57%) had hypomagnesemia. We observed mean SMg (1.7 mg) significantly low in diabetic patients compared with controls (2.1 mg). We also found HbA1c was high (9%) in hypomagnesemia patients. We found that diabetic hypomagnesemic patients had high mean fasting blood glucose (242.6 mg%) and postprandial blood sugar (313 mg%) than controls. How to cite this article Rekha NH, Bharath MS, Channakeshava SP. Study of Prevalence of Hypomagnesemia in Patients with Type II Diabetes Mellitus. J Med Sci 2017;3(2):55-58.

scholarly journals Coronary Heart Disease in Postmenopausal Women with Type II Diabetes Mellitus and the Impact of Estrogen Replacement Therapy: A Narrative Review

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Marouane Boukhris ◽  
Salvatore Davide Tomasello ◽  
Francesco Marzà ◽  
Sonia Bregante ◽  
Francesca Romana Pluchinotta ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiovascular Risk ◽  
Type Ii Diabetes ◽  
Estrogen Replacement Therapy ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Estrogen Replacement ◽  
The Impact

Coronary heart disease is the main cause of death in postmenopausal women (PMW); moreover its mortality exceeds those for breast cancer in women at all ages. Type II diabetes mellitus is a major cardiovascular risk factor and there is some evidence that the risk conferred by diabetes is greater in women than in men. It was established that the deficiency of endogenous estrogens promotes the atherosclerosis process. However, the impact of estrogen replacement therapy (ERT) on cardiovascular prevention remains controversial. Some authors strongly recommend it, whereas others revealed a concerning trend toward harm. This review tries to underlines the different components of cardiovascular risk in diabetic PMW and to define the place of ERT.

Sign in / Sign up

Export Citation Format

Share Document